Waystar Considers Strategic Options, Including Potential Sale

Healthcare software company Waystar is exploring strategic options, including a potential sale, according to sources familiar with the situation. The firm, which provides technology solutions to automate and manage administrative tasks for hospitals and doctors, has enlisted investment bank Evercore to guide the process. This development comes just two years after Waystar went public.

Market Challenges and Valuation

Waystar's market capitalization has recently declined to approximately $4.8 billion, following a 24% drop in its share price this year. This decline is part of a broader downturn affecting the software sector, raising questions about investor appetite for such businesses. The company's strategic positioning as a technology provider rather than a service-oriented business was intended to secure higher valuations, but concerns over the impact of artificial intelligence on software companies have pressured its stock.

The company was formed in 2017 through the merger of healthcare revenue management firms Zirmed and Navicure. Its major investors include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT holds the largest share at 13%, while CPPIB and BlackRock Institutional Trust Company hold 10% and 8% respectively.

Advisory Process and Stakeholder Responses

The advisory process is in its early stages, with sources noting that plans could change and a sale may not proceed. Neither Waystar nor Evercore have commented on the matter. Similarly, EQT declined to provide a statement, while CPPIB and BlackRock have not responded to requests for comment.

Waystar's exploration of a sale is seen as a test of the market's current interest in software companies, particularly those in the healthcare sector. The outcome could influence how investors view technology firms amid evolving industry dynamics.